-
Mashup Score: 0
The fiscal year 2024 Labor, HHS, Education, and Related Agencies spending bill heading for approval by the House Appropriations Committee cuts NIH by $2.8 billion and NCI by $216 million. To access this subscriber-only content please log in or renew your subscription.Looking for IP Login? Our IP Login system is now automatic. If your institution […]
Source: The Cancer LetterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
AACI 2022 annual meeting keynote on the role of mustard gas in cancer researchBy Association of American Cancer Institutes | July 13, 2023 A video of the presentation appears on the Cancer History Project. Johns Hopkins Kimmel Cancer Center explores the history of medical physics in a podcast 50th Anniversary of the Johns Hopkins […]
Source: The Cancer LetterCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @TheCancerLetter: Mustard gas: From deadly weapon to chemotherapy. @AACI_Cancer https://t.co/5neP1OQi9o
-
Mustard gas: From deadly weapon to chemotherapy. @AACI_Cancer https://t.co/5neP1OQi9o
-
-
Mashup Score: 0
Carl H. June received the 2023 DKMS Mechtild Harf Science Award for his outstanding achievements in cancer immunology. To access this subscriber-only content please log in or renew your subscription.Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via […]
Source: The Cancer LetterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@carlhjune receives 2023 DKMS Mechtild Harf Science Award. https://t.co/NxLUx9LyjE https://t.co/6uT2lmyjaO
-
-
Mashup Score: 1SCOTUS decision on denying service to LGBTQ+ people opens doors for discrimination in cancer care - The Cancer Letter - 2 year(s) ago
At first glance, the United States Supreme Court’s 303 Creative LLC. v. Elenis ruling has nothing to do with health care—but, looking deeper, experts in oncology and law are sounding alarms that the decision can be used to discriminate against LGBTQ+ patients. To access this subscriber-only content please log in or renew your subscription.Looking for […]
Source: The Cancer LetterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At first glance, the SCOTUS ruling on 303 Creative LLC. v. Elenis has nothing to do with health care—but, looking deeper, experts in oncology and law are sounding alarms that the decision can be used to discriminate against LGBTQ+ patients. https://t.co/SWjso5tuqW
-
-
Mashup Score: 0Using ctDNA as an endpoint in your cancer clinical trial? FDA wants to hear from you - The Cancer Letter - 2 year(s) ago
Circulating tumor DNA has the potential to not only change the way medical oncologists assess and treat cancer patients, but also how cancer drugs are reviewed, oncology experts at FDA and pharmaceutical companies said in response to research findings published July 11 by a collaboration led by Friends of Cancer Research. To access this subscriber-only […]
Source: The Cancer LetterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Using ctDNA as an endpoint in your cancer clinical trial? FDA wants to hear from you. https://t.co/AkREzN5wWZ
-
-
Mashup Score: 0SCOTUS decision on denying service to LGBTQ+ people opens doors for discrimination in cancer care - The Cancer Letter - 2 year(s) ago
At first glance, the United States Supreme Court’s 303 Creative LLC. v. Elenis ruling has nothing to do with health care—but, looking deeper, experts in oncology and law are sounding alarms that the decision can be used to discriminate against LGBTQ+ patients. To access this subscriber-only content please log in or renew your subscription.Looking for […]
Source: The Cancer LetterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
SCOTUS decision on denying service to LGBTQ+ people opens doors for discrimination in cancer care. https://t.co/SWjso5u2gu
-
-
Mashup Score: 4
The U.S. Preventive Services Task Force’s new guidelines to offer mammography from age 40 will save many lives. To access this subscriber-only content please log in or renew your subscription.Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via […]
Source: The Cancer LetterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The new breast cancer screening guidelines are not enough to save Black women. Guest editorial by Vivian Jolley Bea and @KemiMDRad. #HealthEquity http://https://t.co/c4cCOv6EJ7
-
-
Mashup Score: 0Evaluation of COE requires a holistic approach; avoiding two fundamental fallacies - The Cancer Letter - 2 year(s) ago
Progress against cancer, as brought about by high quality academic cancer centers, requires individual excellence from experts who apply distinct, highly specific skill sets to a common goal within the cancer center. The cancer center coordinates and supports these efforts. To access this subscriber-only content please log in or renew your subscription.Looking for IP Login? […]
Source: The Cancer LetterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Evaluation of COE requires a holistic approach; avoiding two fundamental fallacies. Guest editorial by George Weiner (@UIowaCancer). https://t.co/iIO8Fizm1J
-
-
Mashup Score: 0
The fiscal year 2024 Labor, HHS, Education, and Related Agencies spending bill heading for approval by the House Appropriations Committee cuts NIH by $2.8 billion and NCI by $216 million. To access this subscriber-only content please log in or renew your subscription.Looking for IP Login? Our IP Login system is now automatic. If your institution […]
Source: The Cancer LetterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
House FY24 spending bill slashes @NIH by 6%, @theNCI by 3%. https://t.co/GaPDCanboS
-
-
Mashup Score: 0Can ctDNA be used as an endpoint for cancer drug development? Friends collaboration to present initial results July 11 - The Cancer Letter - 2 year(s) ago
As researchers consider using circulating tumor DNA as an endpoint in clinical trials to evaluate drug efficacy, a collaboration led by Friends of Cancer Research is creating the evidentiary roadmap for the use of ctDNA in regulatory decisions. To access this subscriber-only content please log in or renew your subscription.Looking for IP Login? Our IP […]
Source: The Cancer LetterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The ctMoniTR project seeks to address a specific question: Do changes in ctDNA levels reflect a patient’s response to treatment? https://t.co/wGBJu2456f
-
The fiscal year 2024 Labor, HHS, Education, and Related Agencies spending bill heading for approval by the House Appropriations Committee cuts NIH by $2.8 billion and NCI by $216 million. https://t.co/GaPDCamDzk